Patients with previously untreated advanced squamous non-small-cell lung cancer lived significantly longer without their ...

A new drug called ivonescimab just beat standard immunotherapy in a major lung cancer trial: patients lived nearly four ...

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous ...

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, ...

New dual-action drug a ‘promising step forward’ for patients with hard-to-treat lung cancer - Experts have described the ...

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various ...

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy. Patients with previously untreated advanced squamous non-small cell lung ...

Hernexeos (zongertinib) received FDA accelerated approval for unresectable or metastatic non-squamous NSCLC with HER2 TKD mutations after prior treatment. The Beamion LUNG-1 trial showed a 75% ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jia Luo, MD: Thank ...